Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Spondyloarthropathies

Fine tuning the management of axial spondyloarthritis

Nature Reviews Rheumatology volume 13, pages 199–200 (2017)Cite this article

Subjects

Updated recommendations for the management of axial spondyloarthritis provide a useful framework for physicians treating this disease. However, the guidance on use of biologic therapies and treat-to-target strategies seems to raise more questions than it answers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing spondylitis and axial spondyloarthritis. N. Engl. J. Med. 374, 2563–2574 (2016).

    Article  Google Scholar 

  2. Rudwaleit, M. et al. The development of Assessment of Spondyloarthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777–783 (2009).

    Article  CAS  Google Scholar 

  3. Van der Heijde, D. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2016-210770 (2017).

  4. Wendling, D. et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine 81, 6–14 (2014).

    Article  Google Scholar 

  5. Smolen, J. S. et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann. Rheum. Dis. 73, 6–16 (2014).

    Article  Google Scholar 

  6. Wendling, D. An overview of investigational new drugs for treating ankylosing spondylitis. Expert Opin. Investig. Drugs 25, 95–104 (2016).

    Article  CAS  Google Scholar 

  7. Prati, C. et al. TNFα antagonist therapy in axial spondyloarthritis: can we do better? Joint Bone Spine 83, 247–249 (2016).

    Article  Google Scholar 

  8. Guellec, D. et al. Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis? Joint Bone Spine 81, 308–312 (2014).

    Article  CAS  Google Scholar 

  9. Wach, J. et al. Fibromyalgia in spondyloarthritis: effect on disease activity assessment in clinical practice. J. Rheumatol. 43, 2056–2063 (2016).

    Article  CAS  Google Scholar 

  10. Sieper, J. et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomized placebo-controlled trial (ABILITY-1). Ann. Rheum. Dis. 72, 815–822 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Daniel Wendling is at the Department of Rheumatology, University Teaching Hospital, CHRU de Besançon, Boulevard Alexandre Fleming, 25030 Besançon, France; and at EA4266, Université Bourgogne-Franche-Comté, 32 Avenue de l'Observatoire, 25030 Besançon, France.,

    Daniel Wendling

  2. and at EA4266, Université Bourgogne-Franche-Comté, 32 Avenue de l'Observatoire, 25030 Besançon, France.,

    Daniel Wendling

  3. Clément Prati is at the Department of Rheumatology, University Teaching Hospital, CHRU de Besançon, Boulevard Alexandre Fleming, 25030 Besançon, France; and at EA4267, Fédération Hospitalo-Universitaire Integrates Centre for Research in Inflammatory Diseases (FHU INCREASE), Université Bourgogne-Franche-Comté, 25030 Besançon, France.,

    Clément Prati

  4. and at EA4267, Fédération Hospitalo-Universitaire Integrates Centre for Research in Inflammatory Diseases (FHU INCREASE), Université Bourgogne-Franche-Comté, 25030 Besançon, France.,

    Clément Prati

Authors
  1. Daniel Wendling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clément Prati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Wendling.

Ethics declarations

Competing interests

D.W. declares that he has received speaking fees from, acted as an adviser for or received hospitality from AbbVie, Amgen, BMS, Celgene, Chugai, Eli Lilly, Hospira, Janssen, MSD, Nordic Pharma, Novartis, Pfizer, Roche, Sandoz, Sanofi Aventis, SOBI and UCB. C.P. declares that he has received speaking fees from, acted as an adviser for or received hospitality from BMS, Chugai, Eli Lilly, Hospira, Janssen, Medac, Novartis, Pfizer, Roche and UCB.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wendling, D., Prati, C. Fine tuning the management of axial spondyloarthritis. Nat Rev Rheumatol 13, 199–200 (2017). https://doi.org/10.1038/nrrheum.2017.24

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2017.24

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing